12 patents
Utility
Radioimmunoconjugates and Checkpoint Inhibitor Combination Therapy
31 Aug 23
Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
Eric Steven Burak, Julie Metcalf, Natalie Grinshtein, Meiduo Hu, John Fitzmaurice Valliant
Filed: 15 Aug 22
Utility
FGFR3-TARGETED Radioimmunoconjugates and Uses Thereof
29 Jun 23
Radioimmunoconjugates including a chelating moiety or a metal complex thereof, a linker, and an FGFR3 targeting moiety.
Eric Steven Burak, Marc Schwabish, Natalie Grinshtein
Filed: 23 Mar 21
Utility
Sustained Immunotherapy
23 Mar 23
Methods of inducing CD8+ T cell infiltration into a tumor in a patient in need thereof comprising administering a radioimmunoconjugate that is capable of binding a target expressed by at least some cells in a tumor.
Eric Steven Burak, julie Metcalf, Natalie Grinshtein, Meiduo Hu, John Fitznaurice valliant, Sonal Patel
Filed: 8 Jan 21
Utility
Actinium-225 and checkpoint inhibitor combination therapy
20 Sep 22
Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
Eric Steven Burak, Julie Metcalf, Natalie Grinshtein, Meiduo Hu, John Fitzmaurice Valliant
Filed: 3 Dec 19
Utility
Endosialin-binding Antibody
14 Jul 22
The present disclosure relates to the generation of an antibody that specifically recognizes and binds Endosialin, a cell surface antigen characteristic of tumor pericytes and cells of tumor stroma.
Stefano Iacobelli, Annalisa Di Risio, Enza Piccolo, Gianluca Sala, Emily Capone
Filed: 29 Mar 22
Utility
Endosialin-binding antibody
3 May 22
The present disclosure relates to the generation of an antibody that specifically recognizes and binds Endosialin, a cell surface antigen characteristic of tumor pericytes and cells of tumor stroma.
Stefano Iacobelli, Annalisa Di Risio, Enza Piccolo, Gianluca Sala, Emily Capone
Filed: 3 Feb 17
Utility
Radioimmunoconjugates and Checkpoint Inhibitor Combination Therapy
24 Mar 22
Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
Eric Steven BURAK, Julie METCALF, Natalie GRINSHTEIN, Meiduo HU, John Fitzmaurice VALLIANT
Filed: 3 Dec 19
Utility
Radioimmunoconjugates and Dna Damage and Repair Inhibitor Combination Therapy
24 Mar 22
Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.
Eric Steven BURAK, John Richard FORBES, Meiduo HU, John Fitzmaurice VALLIANT
Filed: 3 Dec 19
Utility
Macrocyclic Chelates and Uses Thereof
23 Dec 21
The present disclosure relates to macrocyclic chelates including a macrocyclic chelating moiety of a metal complex thereof, a bifunctional linker, and a therapeutic or targeting moiety.
Stuart J. Mahoney, Michael B. Johansen, Matthew D. Moran, Melissa Chassé, Ryan W. Simms, Eric S. Burak, John F. Valliant
Filed: 8 Jan 21
Utility
Radioimmunoconjugates and Checkpoint Inhibitor Combination Therapy
23 Sep 21
Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
Eric Steven Burak, Julie Metcalf, Natalie Grinshtein, Meiduo Hu, John Fitzmaurice Valliant
Filed: 2 Jun 21
Utility
Radioimmunoconjugates and Dna Damage and Repair Inhibitor Combination Therapy
23 Sep 21
Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.
Eric Steven Burak, John Richard Forbes, Meiduo Hu, John Fitzmaurice Valliant
Filed: 2 Jun 21
Utility
Methods, Compositions, and Kits for Treatment of Cancer
30 Sep 20
Provided herein are the use of FGFR3 inhibitors and taxanes to treat solid and hematologic cancers, as well as compositions and kits comprising an FGFR3 inhibitor and a taxane.
Jocelyn Holash
Filed: 26 Apr 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first